SIR-Spheres® Y-90 resin microspheres
Reimbursement
Under the terms of the Medicare Prescription Drug Improvement and Modernization Act (MMA) of 2003, Medicare, for the most part, reimburses hospitals for the cost of outpatient treatment with SIR-Spheres® Y-90 resin microspheres.
Many private payers also acknowledge the clinical utility of the SIRT procedure and have issued positive coverage policies for treatment.
Please see coding guides for more information:
*Reimbursement is a third-party determination process evaluated on a case-by-case basis and is not guaranteed by Sirtex.
Indications for Use: SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intrahepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings, and precautions.